3M and IDRI Collaborate in Vaccine Research
Posted on: Friday, 2 May 2008, 09:01 CDT
3M Drug Delivery Systems has signed a non-exclusive license agreement with the Infectious Disease Research Institute in support of vaccine research for humanitarian efforts in developing countries.
Under the agreement, 3M will donate its patented toll-like receptor (TLR) immune response modifier compounds. 3M's patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by the Infectious Disease Research Institute (IDRI) to research new vaccines. Vaccine adjuvants are known to help boost the effectiveness of a vaccine.
According to 3M, TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.
Mark Tomai, head of drug discovery and pre-clinical development at 3M Drug Delivery Systems, said: "IDRI's vaccine platform has the potential to prevent and treat a number of important diseases in the developing world. By providing our vaccine adjuvant compounds to their vaccines, we are providing a cost-effective way for IDRI to conduct vaccine research."
Source: Datamonitor
Related Articles
- Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
- Research and Markets: By 2015 Sales of Products Using Advanced Drug Delivery Technology Assessed Could Exceed US$43 Billion
- Philips and Celsion Announce Research Agreement to Develop New Cancer Treatment That Combines Ultrasound, Drug Delivery Technology
- Research of Patients and Physicians About Drug Delivery Technologies in the U.S. Produces Exciting New Study
- Eurand Award Honors Achievements in Oral Drug Delivery Research
- Research and Markets: The Drug Delivery Sector Continues to Focus on Innovative Methods
- New Study Titled Drug Delivery Systems Estimates That the US Drug Delivery Market Value Might Reach Nearly $85 Billion By 2010
- The Use Of Transdermal Drug Delivery In Depression And Attention Deficit Hyperactivity Disorder Are Poised To Provide Substantial Growth For The Industry
- New Research Profiles 66 Companies That Either Develop Technologies for Drug Delivery to the Cardiovascular System or Products Using These Technologies
 |
 |
User Comments (0)
RSS Feeds